Author:
Parenky Ashwin,Myler Heather,Amaravadi Lakshmi,Bechtold-Peters Karoline,Rosenberg Amy,Kirshner Susan,Quarmby Valerie
Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products [Internet]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf . Accessed Feb 2013.
2. Stirling A, Gee D. Science, precaution, and practice. Public Health Rep Wash DC 1974. 2002 117(6):521–33.
3. Xue L, Rup B. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J. 2013;15(3):893–6.
4. Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The complex clinical picture of side effects to biologicals. Med Clin North Am. 2010;94(4):791–804. xi–ii.
5. Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454–67.
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献